Previous 10 | Next 10 |
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer PR Newswire Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, Chi...
Gainers: Better Therapeutics BTTX +43% . GeoVax Labs ( GOVX ) +22% . Aridis Pharmaceuticals ( ARDS ) +19% . Comera Life Sciences ( CMRA ) +13% . Gracell Biotechnologies ( GRCL ) +13% . Losers: Community Health Systems ( CYH ...
Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , July 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global cli...
Gracell Biotechnologies ( NASDAQ: GRCL ) has announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer. In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including str...
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer PR Newswire SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Compan...
Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...
Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic...
Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients PR Newswire Gracell also presented data on GC012F for treatment of B-NHL and al...
Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 To hold conference call on Monday, June 13 at 8:00 am ET PR Newswire SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , June. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NA...
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting PR Newswire SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 /PRNewsw...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...